Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

11 Pharmacoeconogenomics
A Good Marriage of
Pharmacoeconomics
and Pharmacogenomics
Hong-Guang Xie
CONTENTS
Key Concepts.......................................................................................................... 271
Introduction............................................................................................................. 272
Principles of Pharmacoeconogenomics.................................................................. 273
Cost-Effectiveness Analysis............................................................................... 273
Cost-Utility Analysis.......................................................................................... 274
Cost-Benefit Analysis......................................................................................... 275
Cost-Minimization Analysis.............................................................................. 275
Practice of Pharmacoeconogenomics in Clinical Settings...................................... 275
TPMT and the Thiopurine Drugs.......................................................................277
HER2 and Trastuzumab..................................................................................... 278
HLA B*5701 and Abacavir Hypersensitivity..................................................... 278
CYP2C9 and the Anticoagulant Warfarin........................................................... 279
CYP2C19 and the Antiplatelet Drug Clopidogrel.............................................. 279
Economic Evaluation of Genetic Testing................................................................280
Conclusions and Future Perspectives...................................................................... 281
Acknowledgments...................................................................................................282
Study Questions......................................................................................................282
References...............................................................................................................284
KEY CONCEPTS
• The cost of healthcare is rapidly increasing worldwide, thereby becoming a
common barrier to the widespread use of an expensive new drug, medical
innovation, or biological technology in clinical settings.
• Economic considerations are of paramount importance for optimal selection
of the drug and dosage in patient care.
• Better safety, higher efficacy, and lower cost have been widely recognized
to be the gold standard for optimal drug therapy.
271